Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

Colombo, M; Fernández, I; Abdurakhmanov, D; A Ferreira, P; I Strasser, S; Urbanek, P; Moreno, C; Streinu-Cercel, A; Verheyen, A; Iraqi, W; DeMasi, R; Hill, A; M Läuffer, J; Lonjon-Domanec, I; Wedemeyer, H

doi:10.1136/gutjnl-2013-305667

Public

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

Shared by NobleBlocks on Jul 1, 2014 • 12:00 AM UTC

Authors:

M Colombo

I Fernández

D Abdurakhmanov

Abstract

BACKGROUND AND AIM: Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-...

Subject

ANEMIA

HEPATITIS C

INTERFERON

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!